Loading
A phase 1/2 trial of Bevacizumab, Oxaliplatin and Capecitabine in colorectal cancer, run by Hansoh BioMedical R&D Company, now recruiting.
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. is a phase 1/2 interventional study registered as NCT07283367 by Hansoh BioMedical R&D Company, with 502 participants planned, started 2025-12-22 and due to reach its primary completion in 2029-12-31. Interventions recorded: Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin and Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Bevacizumab, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/